Duane A Burnett

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3087066/publications.pdf

Version: 2024-02-01

56 2,955 25 54
papers citations h-index g-index

61 61 61 2614 all docs docs citations times ranked citing authors

#	Article	IF	CITATIONS
1	Discovery of quinuclidine modulators of cellular progranulin. Bioorganic and Medicinal Chemistry Letters, 2021, 47, 128209.	2.2	3
2	Discovery of the Oxadiazine FRM-024: A Potent CNS-Penetrant Gamma Secretase Modulator. Journal of Medicinal Chemistry, 2021, 64, 14426-14447.	6.4	7
3	Design, Synthesis, and Evaluation of a Novel Series of Oxadiazine Gamma Secretase Modulators for Familial Alzheimer's Disease. Journal of Medicinal Chemistry, 2017, 60, 2383-2400.	6.4	22
4	Strategic and Tactical Approaches to the Synthesis of 5,6-Dihydro-[1,2,4]oxadiazines. Heterocycles, 2016, 92, 2166.	0.7	9
5	Design and synthesis of water soluble \hat{l}^2 -aminosulfone analogues of SCH 900229 as \hat{l}^3 -secretase inhibitors. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 5836-5841.	2.2	3
6	Scaffold-hopping from xanthines to tricyclic guanines: A case study of dipeptidyl peptidase 4 (DPP4) inhibitors. Bioorganic and Medicinal Chemistry, 2016, 24, 5534-5545.	3.0	10
7	Characterization of FRM-36143 as a new \hat{I}^3 -secretase modulator for the potential treatment of familial Alzheimer \hat{I}^{\pm} 8 disease. Alzheimer's Research and Therapy, 2016, 8, 34.	6.2	15
8	Discovery of Novel Tricyclic Heterocycles as Potent and Selective DPP-4 Inhibitors for the Treatment of Type 2 Diabetes. ACS Medicinal Chemistry Letters, 2016, 7, 498-501.	2.8	36
9	Discovery of a Novel, Potent Spirocyclic Series of \hat{I}^3 -Secretase Inhibitors. Journal of Medicinal Chemistry, 2015, 58, 8806-8817.	6.4	20
10	Structure activity relationship studies of tricyclic bispyran sulfone \hat{I}^3 -secretase inhibitors. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 844-849.	2.2	15
11	A-ring modification of SCH 900229 and related chromene sulfone Î ³ -secretase inhibitors. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 850-853.	2.2	1
12	Discovery of SCH 900229, a Potent Presenilin 1 Selective γ-Secretase Inhibitor for the Treatment of Alzheimer's Disease. ACS Medicinal Chemistry Letters, 2012, 3, 892-896.	2.8	14
13	Synthesis and SAR Studies of Fused Oxadiazines as \hat{I}^3 -Secretase Modulators for Treatment of Alzheimer's Disease. ACS Medicinal Chemistry Letters, 2012, 3, 931-935.	2.8	34
14	Synthesis and SAR development of novel mGluR1 antagonists for the treatment of chronic pain. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 7223-7226.	2.2	7
15	Cyclic Hydroxyamidines as Amide Isosteres: Discovery of Oxadiazolines and Oxadiazines as Potent and Highly Efficacious Î ³ -Secretase Modulators in Vivo. Journal of Medicinal Chemistry, 2012, 55, 489-502.	6.4	52
16	Fused tricyclic mGluR1 antagonists for the treatment of neuropathic pain. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 1575-1578.	2.2	20
17	Identification of Presenilin 1-Selective \hat{l}^3 -Secretase Inhibitors with Reconstituted \hat{l}^3 -Secretase Complexes. Biochemistry, 2011, 50, 4973-4980.	2.5	35
18	SAR of tricyclic sulfones as Î ³ -secretase inhibitors. Science China Chemistry, 2011, 54, 1688-1701.	8.2	7

#	Article	IF	CITATIONS
19	Design and synthesis of tricyclic sulfones as \hat{l}^3 -secretase inhibitors with greatly reduced Notch toxicity. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 2591-2596.	2.2	17
20	Remote functionalization of SCH 39166: Discovery of potent and selective benzazepine dopamine D1 receptor antagonists. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 832-835.	2.2	6
21	Discovery of new SCH 39166 analogs as potent and selective dopamine D1 receptor antagonists. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 836-840.	2.2	6
22	A-ring modifications on the triazafluorenone core structure and their mGluR1 antagonist properties. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 2474-2477.	2.2	17
23	Tetracyclic sulfones as potent γ-secretase inhibitors: Synthesis and structure–activity relationship studies. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 3645-3648.	2.2	10
24	Tricyclic sulfones as orally active γ-secretase inhibitors: Synthesis and structure–activity relationship studies. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 3632-3635.	2.2	27
25	T-type calcium channel blockers: spiro-piperidine azetidines and azetidinones—optimization, design and synthesis. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 4602-4606.	2.2	20
26	Iminoheterocycles as \hat{I}^3 -secretase modulators. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 5380-5384.	2.2	30
27	Tricyclic thienopyridine–pyrimidones/thienopyrimidine–pyrimidones as orally efficacious mGluR1 antagonists for neuropathic pain. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 3199-3203.	2.2	26
28	Discovery of Orally Efficacious Tetracyclic Metabotropic Glutamate Receptor 1 (mGluR1) Antagonists for the Treatment of Chronic Pain. Journal of Medicinal Chemistry, 2007, 50, 5550-5553.	6.4	33
29	SAR study of bicyclo[4.1.0]heptanes as melanin-concentrating hormone receptor R1 antagonists: Taming hERG. Bioorganic and Medicinal Chemistry, 2007, 15, 5369-5385.	3.0	11
30	Synthesis of novel bicyclo[4.1.0]heptane and bicyclo[3.1.0]hexane derivatives as melanin-concentrating hormone receptor R1 antagonists. Bioorganic and Medicinal Chemistry Letters, 2007, 17, 4845-4850.	2.2	9
31	Synthesis and structure–activity relationships of piperidine-based melanin-concentrating hormone receptor 1 antagonists. Bioorganic and Medicinal Chemistry Letters, 2006, 16, 3668-3673.	2.2	9
32	Modification of the clozapine structure by parallel synthesis. Bioorganic and Medicinal Chemistry Letters, 2006, 16, 4548-4553.	2.2	36
33	Design and synthesis of orally efficacious benzimidazoles as melanin-concentrating hormone receptor 1 antagonists. Bioorganic and Medicinal Chemistry Letters, 2006, 16 , $3674-3678$.	2.2	18
34	Novel aminobenzimidazoles as selective MCH-R1 antagonists for the treatment of metabolic diseases. Bioorganic and Medicinal Chemistry Letters, 2006, 16, 5427-5431.	2.2	16
35	The target of ezetimibe is Niemann-Pick C1-Like 1 (NPC1L1). Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 8132-8137.	7.1	685
36	Dopamine D1/D5 Receptor Antagonists with Improved Pharmacokinetics:  Design, Synthesis, and Biological Evaluation of Phenol Bioisosteric Analogues of Benzazepine D1/D5 Antagonists. Journal of Medicinal Chemistry, 2005, 48, 680-693.	6.4	85

#	Article	IF	Citations
37	β-Lactam Cholesterol Absorption Inhibitors. Current Medicinal Chemistry, 2004, 11, 1873-1887.	2.4	124
38	Synthesis and Structureâ€"Activity Relationships of Aminoalkylazetidines as ORL1 Receptor Ligands ChemInform, 2003, 34, no.	0.0	0
39	The identification of intestinal scavenger receptor class B, type I (SR-BI) by expression cloning and its role in cholesterol absorption. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2002, 1580, 77-93.	2.4	138
40	Synthesis of iodinated biochemical tools related to the 2-azetidinone class of cholesterol absorption inhibitors. Bioorganic and Medicinal Chemistry Letters, 2002, 12, 311-314.	2.2	25
41	Synthesis of fluorescent biochemical tools related to the 2-azetidinone class of cholesterol absorption inhibitors. Bioorganic and Medicinal Chemistry Letters, 2002, 12, 315-318.	2.2	14
42	Synthesis and structure–activity relationships of aminoalkylazetidines as ORL1 receptor ligands. Bioorganic and Medicinal Chemistry Letters, 2002, 12, 3157-3160.	2.2	16
43	Chapter 6. Recent advances in the science and treatment of atherosclerosis. Annual Reports in Medicinal Chemistry, 2001, 36, 57-66.	0.9	0
44	Structure-activity relationships of pyrroloquinazolines as thrombin receptor antagonists. Bioorganic and Medicinal Chemistry Letters, 1999, 9, 2073-2078.	2.2	52
45	An enzymatic synthesis of glucuronides of azetidinone-based cholesterol absorption inhibitors. Bioorganic and Medicinal Chemistry, 1999, 7, 2199-2202.	3.0	14
46	Discovery of 1-(4-Fluorophenyl)-(3R)-[3-(4-fluorophenyl)-(3S)-hydroxypropyl]-(4S)-(4-hydroxyphenyl)-2-azetidinone (SCH 58235):Â A Designed, Potent, Orally Active Inhibitor of Cholesterol Absorption. Journal of Medicinal Chemistry, 1998, 41, 973-980.	6.4	355
47	2-Azetidinone Cholesterol Absorption Inhibitors:Â Structureâ^'Activity Relationships on the Heterocyclic Nucleus. Journal of Medicinal Chemistry, 1996, 39, 3684-3693.	6.4	125
48	Trans diastereoselective synthesis of 3-alkyl substituted \hat{l}^2 -lactams via the acid chloride-imine reaction of nonactivated acid chlorides. Tetrahedron Letters, 1995, 36, 2555-2558.	1.4	55
49	Hypocholesterolemic activity of a novel inhibitor of cholesterol absorption, SCH 48461. Atherosclerosis, 1995, 115, 45-63.	0.8	109
50	Asymmetric synthesis and absolute stereochemistry of cholesterol absorption inhibitor, SCH 48461. Tetrahedron Letters, 1994, 35, 7339-7342.	1.4	47
51	2-Azetidinones as Inhibitors of Cholesterol Absorption. Journal of Medicinal Chemistry, 1994, 37, 1733-1736.	6.4	210
52	betaStannyl enones as radical traps: a very direct route to PGF2.alpha Journal of Organic Chemistry, 1987, 52, 2958-2960.	3.2	60
53	Conformational effects on the oxidative coupling of benzyltetrahydroisoquinolines to morphinan and aporphine alkaloids. Journal of Organic Chemistry, 1987, 52, 5662-5667.	3.2	28
54	.betaLactams from esters and sulfenimines: a new route to monobactams. Journal of Organic Chemistry, 1986, 51, 1929-1930.	3.2	34

#	Article	lF	CITATIONS
55	Synthesis of 3-(1-hydroxyethyl)-2-azetidinones via ester-imine condensations. Journal of Organic Chemistry, 1985, 50, 5120-5123.	3.2	26
56	Pyrrolizidinone and indolizidinone synthesis: generation and intramolecular addition of alphaacylamino radicals to olefins and allenes. Journal of the American Chemical Society, 1984, 106, 8201-8209.	13.7	151